Material Event - Form 425

Item 5.07 Submission of Matters to a Vote of Security Holders.

(a) On December 2, 2024, Pieris Pharmaceuticals, Inc. (the "Company" or "Pieris") held its 2024 annual meeting of stockholders (the "Annual Meeting"). Of the 1,320,240 shares of common stock of the Company issued and outstanding and eligible to vote as of the record date of October 25, 2024, a quorum of 1,020,443 shares of common stock, or 77.29% of the outstanding shares, were present in person or by proxy.

(b) At the Annual Meeting, the stockholders: (1) elected each of Chris Kiritsy and Peter Kiener, D.Phil. to the Company's Board of Directors as Class I directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders ("Election of Directors"); (2) ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 ("Auditor Ratification"); and (3) approved, on a non-binding basis, the compensation of named executive officers ("Say on Pay"). A more complete description of each of these matters is set forth in the Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission ("SEC") on November 6, 2024.

The number of votes cast in favor or against or withheld by the stockholders and, where applicable, the number of abstentions and the number of broker non-votes on each of the foregoing matters are set forth below.

1. Election of Directors

Name	Votes For	Votes Withheld	Broker Non-Votes
Chris Kiritsy	593,528	18,274	408,641
Peter Kiener, D.Phil.	593,558	18,244	408,641

2. Auditor Ratification

Votes For	Votes Against	Votes Abstained	Broker Non-Votes
1,017,470	2,439	534	-

3. Say on Pay

Votes For	Votes Against	Votes Abstained	Broker Non-Votes
604,490	6,678	634	408,641

Public link

Please use the above public link if you want to share this noodl on another website.